Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent.

Published byGabriel Robbins Modified over 5 years ago

Similar presentations

Presentation on theme: "Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent."— Presentation transcript:

1 Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent excess (MPE). ▴, amino acids plus glucose (AAG) dialysis; ▵, glucose dialysis. Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent excess (MPE). ▴, amino acids plus glucose (AAG) dialysis; ▵, glucose dialysis. Hoey Lan Tjiong et al. CJASN 2007;2:74-80 ©2007 by American Society of Nephrology

Download ppt "Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover (WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent."

Similar presentations

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.

Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.
Model of human CLC-Kb transporter topology and positions of amino acid exchanges due to mutations in the CLCNKB gene as identified in Bartter syndrome.

Model of human CLC-Kb transporter topology and positions of amino acid exchanges due to mutations in the CLCNKB gene as identified in Bartter syndrome.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.

Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Schematic describing metabolism of selected amino acids and the related production of metabolic stimulus-secretion coupling factors involved in insulin.

Schematic describing metabolism of selected amino acids and the related production of metabolic stimulus-secretion coupling factors involved in insulin.
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)
Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Similar presentations

Ads by Google